Molecular Medicine Reports Molecular Medicine Reports 1791-2997 1791-3004 D.A. Spandidos 10.3892/mmr.2018.8674 mmr-17-05-6881 Articles Neuroprotective effect of berberine agonist against impairment of learning and memory skills in severe traumatic brain injury via Sirt1/p38 MAPK expression WangJianping 1 ZhangYamin 2 Department of Emergency, Gansu Provincial Hospital, Lanzhou, Gansu 730000, P.R. China Department of Neurological Rehabilitation, Gansu Provincial Hospital, Lanzhou, Gansu 730000, P.R. China Correspondence to: Dr Jianping Wang, Department of Emergency, Gansu Provincial Hospital, 204 Donggang West Road, Lanzhou, Gansu 730000, P.R. China, E-mail: wzekyr2926206@126.com 052018 05032018 17 5 6881 6886 22012017 20092017 Copyright © 2018, Spandidos Publications 2018

Berberine has multiple clinical applications, including the treatment of tumors, diabetes, cardiovascular diseases, hyperlipidemia, inflammation, bacterial and viral infections, cerebral ischemic injuries, mental diseases, Alzheimer's disease and osteoporosis. In the present study, the neuroprotective effect of berberine agonist rescue learning and memory in severe traumatic brain injury (TBI), and the possible mechanism underlying these observations was explored. The protective effect of berberine agonist significantly recovered learning and memory skills, attenuated brain edema and inhibited matrix metalloproteinase-3 and −9 protein expression in mice with severe TBI. Berberine agonist significantly reduced inflammation, oxidative stress and apoptosis levels in mice with severe TBI. Berberine agonist promoted choline acetyltransferase activity and inhibited the activity of acetylcholinesterase. Collectively, results of the present study revealed that the neuroprotective effect of berberine agonist rescues learning and memory skills in severe TBI.

 berberine severe traumatic brain injury learning and memory p38 mitogen-activated protein kinase Introduction

Traumatic brain injury (TBI) is a prevalent disease in modern society. The fatality and disability rates of TBI are the highest among traumas of human organs (1). The incidence of TBI in USA is ~2%, and 500,000 new TBI cases are recorded annually, including 10% severe TBI, which leads to ~20,000 mortality and 30,000 disability cases, resulting in significant direct and indirect economic losses (2). With the rapid development of the global economy and modern transportation, TBI has become an important human health issue (1). Therefore, research groups are attempting to alleviate TBI-induced neurological impairment, and improve the effectiveness of the treatment of TBI (3). TBI and the resulting pathological condition are major factors endangering human health. Sequelae of TBI include post-TBI learning and memory skill impairment, which influence the quality of life of patients (4).

TBI-induced neural death is the most prevalent cause of death in patients. Inhibition of post-injury cell death and preservation of neurons is the research focus of TBI (5). Inhibition of the cell death pathway and fundamental reduction of neuronal death is a potential treatment approach (6). Cell death can be classified into two categories, cell apoptosis and cell necrosis. Apoptosis is programmed cell death regulated by gene expression, while necrosis represents an unregulated and irreversible passive cell death (7).

Numerous biologically active natural products isolated from Chinese medical herbs frequently demonstrate physiological functions. An appropriate structural modification of these herbs may lead to the development of novel drugs with high activity and specificity (8). Drug research and development in China should focus on carrying out innovative drug research based on biologically active natural products native to China (9). Many biologically active natural products extracted from Chinese herbal medicine, including berberine, have been extensively applied in medical practice. Berberine (Fig. 1) is an isoquinoline alkaloid derived from Coptis chinensis, a plant species native to China (9). Berberine and its derivatives demonstrate multiple pharmacological effects on tumor treatment, diabetes, cardiovascular disease, hyperlipidemia, inflammation, bacterial and viral infection, cerebral ischemic injury, mental disease, Alzheimer's disease and osteoporosis (10). The aim of the present study was to determine the neuroprotective effect of berberine on learning and memory skills in severe TBI, and to explore the underlying molecular mechanism.

 Materials and methods <sec> <title>Animals and treatment groups

Male C57BL/6J mice (6–7 weeks old; weight, 20–22 g) were obtained from the National Laboratory Animal Center of Gansu Medical College (Lanzhou, China). All animals were randomly allocated into one of three groups: i) Control; ii) TBI model; and iii) berberine agonist treatment. Mice were anesthetized with an intraperitoneal injection (I.I) of sodium pentobarbital (65 mg/kg; Sigma-Aldrich; Merck KGaA, Darmstadt, Germany), and 5 mm craniotomy was performed at the right parietal cortex. Controlled cortical impact was induced using a pneumatic piston with a 2.5 mm rounded metal tip. The bone flap was replaced and sealed, and the scalp was sterilized with iodophor (Sangon Biotech Co., Ltd., Shanghai, China) and sutured. Temperature of the heated cage was maintained at 37.0±0.5°C using a heated pad. Following injury, mice were administered 10 mg/kg/day berberine (Sigma-Aldrich; Merck KGaA) via intraperitoneal injection for 4 weeks. The present study was approved by the Ethics Committee of Gansu Provincial Hospital (Gansu, China).

 Morris water maze test

Following treatment with berberine agonist, mice were subjected to a Morris water maze test (Gansu Medical College, Gansu, China; 1×0.5×0.4 m; 23±2°C). Mice learned how to navigate the maze for 4 days, and then the probe trial was removed. The time it took for mice to pass through the maze and find a platform was recorded and called the escape latency.

 Measurement of inflammation and oxidation

Peripheral blood was collected following treatment with berberine agonist and centrifuged at 2,000 × g for 10 min at 4°C. ELISA for glutathione peroxidase 1 (GSH-PX; S0055), glutathione synthetase (GSH; S0053), superoxide dismutase (SOD; S0109), malondialdehyde (MDA; S0131), tumor necrosis factor-α (TNF-α; PT512) and interleukin (IL)-6 (PI326) levels was performed using commercially available kits (Beyotime Institute of Biotechnology). Choline acetyltransferase (ChAT) and acetylcholinesterase (AchE) levels were performed using commercially available kits (A079-1 and A024 respectively; Nanjing Jiancheng Biology Engineering Institute, Nanjing, China).

 Western blotting

Protein homogenates were prepared from hippocampal tissues using a radioimmunoprecipitation assay (RIPA; Beyotime Institute of Biotechnology), and centrifuged at 12,000 × g for 10 min at 4°C. Protein content was measured using a bicinchoninic acid assay. Proteins (50 µg/per lane) were separated by 8–10% SDS-PAGE and transferred to a polyvinylidene difluoride membrane. The membrane was blocked using 5% skimmed milk in TBS with Tween-20 and incubated with matrix metalloproteinase (MMP)-3 (sc-374029; 1:300), MMP-9 (sc-10737; 1:300), caspase-3 (sc-98785; 1:500), sirtuin 1 (Sirt1; sc-15404; 1:500), phosphorylated (p)-p38 (sc-101759; 1:500) and GAPDH (sc-25778; 1:500; all Santa Cruz Biotechnology, Inc., Dallas, TX, USA) primary antibodies at 4°C overnight. Following washing with TBST for 15 min, membranes were incubated with a horseradish peroxidase-linked anti-rabbit or anti-mouse secondary antibody (sc-2004 or sc-2020; 1:2,000; Santa Cruz Biotechnology, Inc.) for 2 h at 37°C and detected using Pierce enhanced chemifluorescent western blotting substrate (cat. no. 321109; Thermo Fisher Scientific, Inc., Waltham, MA, USA).

 Statistical analysis

Data are presented as the mean ± standard deviation using SPSS version 17.0 (SPSS, Inc., Chicago, IL, USA). One-way or two-way analysis of variance followed by Bonferroni's post hoc test was used for multiple group comparisons. P<0.05 was considered to indicate a statistically significant difference.

 Results <sec> <title>Protective effect of berberine agonist evidenced by Morris water maze test

Berberine (Fig. 1) is an isoquinoline alkaloid derived from Coptis chinensis, a plant species native to China (9). To investigate whether the protective effect of berberine agonist rescues learning and memory skills in severe TBI, TBI mice were treated with berberine agonist. As presented in Fig. 2A and B, a significant increase in escape latency and a longer mean path length were observed in the TBI model group compared with the control group. The time spent in the target quadrant and the number of times mice crossed the platform was decreased in the TBI model group compared with the control group (Fig. 2C and D). However, the treatment with berberine agonist significantly reversed the changes compared with the TBI mice (Fig. 2).

 Protective effect of berberine agonist on choline acetyltransferase (ChAT) and acetylcholinesterase (AchE) activity

Compared with the control group, TBI inhibited ChAT activity and induced AchE activity in untreated TBI mice (Fig. 3). Berberine significantly promoted ChAT activity and inhibited AchE activities in treated TBI mice, compared with the TBI model group (Fig. 3).

 Protective effect of berberine agonist on MMP-3 and −9 protein expression

Following treatment with berberine agonist, protein expression of MMP-3 and −9 in the TBI model group was increased compared with the control group (Fig. 4). The increase of MMP-3/9 protein expressions in TBI mice was significantly suppressed by berberine agonist treatment (Fig. 4).

 Protective effect of berberine agonist on oxidative responses in mice

The effect of berberine agonist on TBI, GSH-PX, GSH and SOD activity, and MDA content was measured. GSH-PX, GSH and SOD activity was significantly inhibited and MDA level was significantly increased in the TBI model group compared with the control group (Fig. 5). Treatment with berberine agonist significantly increased GSH-PX, GSH and SOD activity and reduced the MDA level compared with the TBI mice (Fig. 5).

 Protective effect of berberine on inflammation in mice

To determine whether berberine agonist had an effect on inflammation in TBI, TNF-α and IL-6 levels were measured. As presented in Fig. 6, the abundance of TNF-α and IL-6 increased in the TBI group compared with the control group. Berberine agonist significantly attenuated TNF-α and IL-6 levels compared with untreated TBI mice (Fig. 6).

 Protective effect of berberine agonist on apoptosis levels in TBI

To explore the neuroprotective potential of berberine agonist in the treatment of TBI, the anti-apoptotic effects were explored. TBI induced a significant increase of caspase-3 activity and apoptosis regulator BAX (Bax) protein expression, compared with the control group (Fig. 7). Treatment with berberine agonist significantly suppressed caspase-3 activity and Bax protein expression in the treated TBI group compared with the untreated mice with TBI (Fig. 7).

 Protective effect of berberine agonist on Sirt1 protein expression in TBI

To determine the effect of berberine agonist on Sirt1/FoxO3α protein expression, Sirt1 and p38 mitogen-activated protein kinase (MAPK) protein expression were measured. The Sirt1 protein expression in the TBI group was lower compared with the control group, and p38 MAPK protein expression in the TBI group was higher than in the control group (Fig. 8). Treatment with berberine agonist significantly induced Sirt1 protein expression and suppressed p38 MAPK protein expression in the treated TBI group compared with the untreated TBI group (Fig. 8).

 Discussion

TBI is a common trauma, with second highest morbidity and highest fatality and disability rates among systemic traumas, making it a prevalent issue in modern society (11). Severe (s)TBI demonstrates high fatality and disability rates, and poor prognosis (12). At present, sTBI is not curable, and the treatment for sTBI remains a challenge for neurosurgeons (13). The results of the present study demonstrated that the neuroprotective effect of berberine agonist rescues learning and memory in severe TBI.

TBI can be divided into primary and secondary injury stages. The primary injury occurs immediately after injury, is irreversible, and drug interventions are frequently ineffective. The secondary injury induces changes in the intracerebral environment, aggravates the primary disease, and is characterized by long duration and poor prognosis (14). Traditional craniotomy and drug therapy save lives of numerous patients suffering from sTBI, but pathological processes such as secondary cerebral neuron apoptosis and necrosis induced by all kinds of neuron damage factors (including glutamic acid, calcium overload, radical and inflammatory mediators) during the primary injury and perioperative period, cannot be inhibited (15). Efficient reduction of secondary cerebral injury is key to improving the prognosis for TBI patients (15). The mechanism of TBI is complex and involves excessive post-traumatic release of excitatory amino acids, inflammatory response, imbalance of the activity ion channels, hydrocephalus, oxygen radical production and neural death acting simultaneously to trigger a chain reactions, which eventually lead to death of neurons (6,16). In the present study, the protective effect of berberine agonist significantly attenuated inflammation, oxidation and apoptosis levels in severe TBI mice. Yang et al (8) previously demonstrated that berberine exerts an anti-inflammatory role in ocular Behcet's disease.

Post-TBI neural death can be divided into a primary and secondary death. The primary death is referred to as a direct cell death induced by cell membrane disintegration, and the secondary or delayed cell death occurs around and away from the injury sites, and is caused by trauma-induced physiological or biochemical changes in cells (16). Research on the central nervous system cell death remains challenging, as characteristics of dead neurons are different from that of other dead tissue cells even at an ultrastructure level (17). The results of the present study demonstrated the protective effect that Jin et al (10) previously reported, in which Berberine enhances autophagy and mitigates high glucose-induced apoptosis of mouse podocytes through anti-apoptosis effects.

Multiple cells in brain tissue can produce MMPs, including glial cells, microglia, capillary endothelial cells, macrophages and neutrophils (18). MMPs share a common molecular structure of a signal peptide, propeptide and a catalytic domain from the N- to C-terminal, respectively (10). A predominant function of MMPs is degradation of extracellular matrices, and main components of the basement membrane of blood vessel, including gelatin, type IV and V collagens, cohesin, elastin and fibronectin (10,19). An MMP molecule can directly degrade a certain type or several types of extracellular matrices, or exert its function through the activation of other types of MMPs, initiating a cascade effect (20). MMPs serve important roles in the normal embryonic development and tissue modeling, and in the genesis and development of some diseases including membranous nephropathy, polycystic kidney, atherosclerosis, multiple connective tissue diseases, arthritis and tumor metastasis (21). In the present study, berberine agonist significantly suppressed MMP-3 and −9 proteins in severe TBI mice. Ma et al (10) suggested that berberine inhibits Chlamydophila pneumoniae infection-induced vascular smooth muscle cell migration by downregulating the expression levels of MMP-3 and −9.

Choline acetyltransferase (ChAT) is the generating enzyme of intracerebral neurotransmitter acetylcholine (ACh) involved in learning and memory skills. ChAT abundance in memory-associated cerebral regions is positively correlated with learning and memory abilities (22). ChAT is a marker for cholinergic neurons frequently used to estimate the amount of ACh released by neurons (23). ChAT is synthesized in cholinergic neuron cell bodies and distributed almost parallel to Ach (24). Zhang et al (25) demonstrated that berberine attenuates brain injury in an aluminum-induced rat model of neurodegenerative disease.

In conclusion, the present study demonstrated that the neuroprotective effect of berberine agonist rescues learning and memory skills in severe TBI, through anti-inflammation, anti-oxidation and anti-apoptotic effects. This is, to the best of our knowledge, the first report indicating that berberine agonist may have a neuroprotective effect on learning and memory through regulation of Sirt1/p38 MAPK expression.

 Acknowledgements

Not applicable.

 Funding

No funding was received.

 Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

 Authors' contributions

JW and YZ contributed to the study concept and design, JW wrote the paper, JW and YZ performed the experiments and JW and YZ revised the article and approved the final version for publication.

 Ethics approval and consent to participate

The present study was approved by the Ethics Committee of Gansu Provincial Hospital (Gansu, China).

 Consent for publication

Not applicable.

 Competing interests

The authors declare no competing interests.

 References WadeSLKurowskiBGKirkwoodMWZhangNCassedyABrownTMNielsenBStancinTTaylorHGOnline problem-solving therapy after traumatic brain injury: A randomized controlled trialPediatrics135e487e495201510.1542/peds.2014-1386255839114306792 HammondFMAlexanderDNCutlerAJD'AmicoSDoodyRSSauveWZorowitzRDDavisCSShinPLedonFPRISM II: An open-label study to assess effectiveness of dextromethorphan/quinidine for pseudobulbar affect in patients with dementia, stroke or traumatic brain injuryBMC Neurol1689201610.1186/s12883-016-0609-0272769994899919 WangXJiJFenLWangAEffects of dexmedetomidine on cerebral blood flow in critically ill patients with or without traumatic brain injury: A prospective controlled trialBrain Inj2716171622201310.3109/02699052.2013.83113024102571 SaxenaMKTaylorCBillotLBompointSGowardmanJRobertsJALipmanJMyburghJThe effect of paracetamol on core body temperature in acute traumatic brain injury: A randomised, controlled clinical trialPLoS One10e0144740201510.1371/journal.pone.0144740266787104683067 DuGZhaoZChenYLiZTianYLiuZLiuBSongJQuercetin attenuates neuronal autophagy and apoptosis in rat traumatic brain injury model via activation of PI3K/Akt signaling pathwayNeurol ResOct32016(Epub ahead of print)10.1080/01616412.2016.12403934930388 ChuangCHHsuYCWangCCHuCKuoJRCerebral blood flow and apoptosis-associated factor with electroacupuncture in a traumatic brain injury rat modelAcupunct Med31395403201310.1136/acupmed-2013-01040624055977 HuZGWangHDQiaoLYanWTanQFYinHXThe protective effect of the ketogenic diet on traumatic brain injury-induced cell death in juvenile ratsBrain Inj23459465200910.1080/0269905090278846919408168 YangYWangQXieMLiuPQiXLiuXLiZBerberine exerts an anti-inflammatory role in ocular Behcet's diseaseMol Med Rep1597102201710.3892/mmr.2016.598027922688 HabtemariamSBerberine and inflammatory bowel disease: A concise reviewPharmacol Res113592599201610.1016/j.phrs.2016.09.04127697643 MaLZhangLWangBWeiJLiuJZhangLBerberine inhibits Chlamydia pneumoniae infection-induced vascular smooth muscle cell migration through downregulating MMP3 and MMP9 via PI3KEur J Pharmacol755102109201510.1016/j.ejphar.2015.02.03925746423 NICE-SUGAR Study Investigators for the Australian and New Zealand Intensive Care Society Clinical Trials Group and the Canadian Critical Care Trials GroupFinferSChittockDLiYFosterDDhingraVBellomoRCookDDodekPHebertPIntensive versus conventional glucose control in critically ill patients with traumatic brain injury: Long-term follow-up of a subgroup of patients from the NICE-SUGAR studyIntensive Care Med4110371047201510.1007/s00134-015-3757-626088909 MatusevicieneGBorgJStålnackeBMUlfarssonTde BoussardCEarly intervention for patients at risk for persisting disability after mild traumatic brain injury: A randomized, controlled studyBrain Inj27318324201310.3109/02699052.2012.75074023438351 NägeliMFasshauerMSommerfeldJFendelABrandiGStoverJFProlonged continuous intravenous infusion of the dipeptide L-alanine-L-glutamine significantly increases plasma glutamine and alanine without elevating brain glutamate in patients with severe traumatic brain injuryCrit Care18R139201410.1186/cc13962249929484227121 LiuSZhangLWuQWuQWangTChemokine CCL2 induces apoptosis in cortex following traumatic brain injuryJ Mol Neurosci5110211029201310.1007/s12031-013-0091-823934512 GeXHuangSGaoHHanZChenFZhangSWangZKangCJiangRYueSmiR-21-5p alleviates leakage of injured brain microvascular endothelial barrier in vitro through suppressing inflammation and apoptosisBrain Res16503140201610.1016/j.brainres.2016.07.01527421180 BentzKMolcanyiMSchneiderARiessPMaegeleMBoscheBHamplJAHeschelerJPatzSSchäferUExtract derived from rat brains in the acute phase following traumatic brain injury impairs survival of undifferentiated stem cells and induces rapid differentiation of surviving cellsCell Physiol Biochem26821830201010.1159/00032399121220913 LiuSJZouYBeleguVLvLYLinNWangTYMcDonaldJWZhouXXiaQJWangTHCo-grafting of neural stem cells with olfactory en sheathing cells promotes neuronal restoration in traumatic brain injury with an anti-inflammatory mechanismJ Neuroinflammation1166201410.1186/1742-2094-11-66246900893977666 ReinhardSMRazakKEthellIMA delicate balance: Role of MMP-9 in brain development and pathophysiology of neurodevelopmental disordersFront Cell Neurosci9280201510.3389/fncel.2015.00280262839174518323 GrosseteteMPhelpsJArkoLYonasHRosenbergGAElevation of matrix metalloproteinases 3 and 9 in cerebrospinal fluid and blood in patients with severe traumatic brain injuryNeurosurgery65702708200910.1227/01.NEU.0000351768.11363.48198343752764327 Wiggins-DohlvikKMerrimanMShajiCAAlluriHGrimsleyMDavisMLSmithRWTharakanBTumor necrosis factor-α disruption of brain endothelial cell barrier is mediated through matrix metalloproteinase-9Am J Surg208954960201410.1016/j.amjsurg.2014.08.01425312844 WangYFanXTangTFanRZhangCHuangZPengWGanPXiongXHuangWHuangXRhein and rhubarb similarly protect the blood-brain barrier after experimental traumatic brain injury via gp91phox subunit of NADPH oxidase/ROS/ERK/MMP-9 signaling pathwaySci Rep637098201610.1038/srep37098279010235128794 DixonCEFlinnPBaoJVenyaRHayesRLNerve growth factor attenuates cholinergic deficits following traumatic brain injury in ratsExp Neurol146479490199710.1006/exnr.1997.65579270059 ChaYLeeSHJangSKGuoHBanYHParkDJangGYYeonSLeeJYChoiEKA silk peptide fraction restores cognitive function in AF64A-induced Alzheimer disease model rats by increasing expression of choline acetyltransferase geneToxicol Appl Pharmacol3144854201710.1016/j.taap.2016.11.00827871887 PinedaRGNeilJDierkerDSmyserCDWallendorfMKidokoroHReynoldsLCWalkerSRogersCMathurAMAlterations in brain structure and neurodevelopmental outcome in preterm infants hospitalized in different neonatal intensive care unit environmentsJ Pediatr16452–60e2201410.1016/j.jpeds.2013.08.047 ZhangJYangJQHeBCZhouQXYuHRTangYLiuBZBerberine and total base from rhizoma Coptis chinensis attenuate brain injury in an aluminum-induced rat model of neurodegenerative diseaseSaudi Med J30760766200919526156

Chemical structure of berberine.

Effect of berberine agonist on Morris water maze test. (A) Effect of berberine agonist on the escape latency. (B) Mean path length. (C) Amount of time to reach the target quadrant. (D) Number of times mice crossed the platform. Data are presented as the mean ± standard deviation. **P<0.01 vs. the control group; ##P<0.01 vs. the TBI group. TBI, traumatic brain injury.

Effect of berberine on ChAT and AchE activity in TBI. (A) Changes in ChAT; and (B) AchE activity. Data are presented as the mean ± standard deviation. **P<0.01 vs. the control group; ##P<0.01 vs. the TBI group. ChAT, choline acetyltransferase; AchE, acetylcholinesterase; TBI, traumatic brain injury.

Effect of berberine agonist on MMP-3 and −9 protein expression. (A) Western blotting of MMP-3 and −9. (B) Quantitative analysis of MMP-3 and −9 protein expression. Data are presented as the mean ± standard deviation. **P<0.01 vs. the control group; ##P<0.01 vs. the TBI Group. MMP, matrix metalloproteinase; TBI, traumatic brain injury; MMP, matrix metalloproteinase.

Effect of berberine agonist on oxidative responses. (A) Activity of GSH-PX; (B) GSH; and (C) SOD in mice. (D) MDA levels in mice. Data are presented as the mean ± standard deviation. **P<0.01 vs. the control group; ##P<0.01 vs. the TBI group. TBI, traumatic brain injury; GSH-PX, glutathione peroxidase 1; GSH, glutathione synthetase; SOD, superoxide dismutase; MDA, malondialdehyde.

Effect of berberine agonist on inflammation. Levels of (A) TNF-α; and (B) IL-6 levels in mice. Data are presented as the mean ± standard deviation. **P<0.01 vs. the control group; ##P<0.01 vs. the TBI group. TBI, traumatic brain injury; TNF-α, tumor necrosis factor-α; IL, interleukin.

Effect of berberine agonist on apoptosis. (A) Caspase-3 activity in mice. (B) Western blotting assay of Bax protein expression. (C) Quantitative analysis of Bax protein expression in mice. Data are presented as the mean ± standard deviation. **P<0.01 vs. the control group; ##P<0.01 vs. the TBI group. TBI, traumatic brain injury; Bax, apoptosis regulator BAX.

Effect of berberine agonist on Sirt1/p38 MAPK protein expression in mice. (A) Western blot of Sirt1 and p38 MAPK proteins in mice. (B) Quantitative analysis of Sirt1; and (C) p-p38 MAPK protein expression in mice. **P<0.01 vs. the control group; ##P<0.01 vs. the TBI group. Sirt1, sirtuin-1; MAPK, mitogen-activated protein kinase; TBI, traumatic brain injury.